Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355624 | 0.85 | PDE4B (0.57) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7360400 | 0.80 | PDE4B (0.67) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5823060 | 0.80 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL8202230 | 0.80 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DGAK | |
| SCHEMBL7417302 | 0.79 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4DGAK | |
| SCHEMBL8204138 | 0.79 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DGAK | |
| SCHEMBL8632255 | 0.77 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5823358 | 0.77 | PDE4A (0.77) | PDE4APDE4BPDE4CPDE4DGAK | |
| SCHEMBL497727 | 0.77 | PDE4A (0.57) | PDE4APDE4BPDE4CPDE4DFPR2 | |
| SCHEMBL7474371 | 0.77 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011114103-A1 | PYRIMIDINONES FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2010029299-A1 | PYRIMIDINONE DERIVATIES FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2010-03-18 | — | — | WO | disclosed |